BioSpace News Archive

Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that preliminary clinical data evaluating APL-2 (pegcetacoplan) in complement 3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington D.C. from Nov. 5 - 10.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the latest advanced wound care research on Apligraf® and NuShield® will be presented at the Symposium on Advanced Wound Care (SAWC) Fall 2019 meeting, held Oct. 12-14 in Las Vegas.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the resignation of Steve Sanghi from its Board of Directors to focus on his duties as CEO and Board Chairman of Microchip Technology Inc.

3M today announced it has completed the acquisition of Acelity, Inc. and its KCI subsidiaries worldwide from a consortium comprised of funds advised by Apax Partners, together with controlled affiliates of the Canada Pension Plan Investment Board and the Public Sector Pension Investment Board for a total enterprise value of approximately $6.7 billion, including assumption of debt and other adjustments.

WestCMR Offers Incentives to Perform Sustainable Practices Year-Round

Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks

TherapeuticsMD, Inc. announced the presentation of ANNOVERA™ findings at the annual meeting of the American Society for Reproductive Medicine being held in Philadelphia, PA on October 12-16, 2019.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Steven Dowdy, Ph.D., to its scientific advisory board (SAB)

Continuing its pursuit to establish premier events for baseline transactions of hemp and CBD (cannabidiol) products, Southern Hemp Marketplace (SHM), LLC., today announced that Eurofins Quality Trait Analysis (QTA) will join its first-ever International Hemp Auction and Market (IHAM) as an official lab analysis partner.

Sophisticated image analyses and other tests will characterize neurological and behavioral outcomes for infants exposed to opioids in the womb